06/21/22 8:00 AMNasdaq : NMTR clinical trial9 Meters Biopharma Announces Interim Analysis of Phase 3 Study of Larazotide for Celiac Disease Does Not Support Trial Continuation9 Meters Biopharma, Inc. (NASDAQ:NMTR), aRHEA-AIneutral
06/13/22 4:35 PMNasdaq : NMTR conferences9 Meters Biopharma to Participate in the 2022 BIO International Convention9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced the Company's participation in the 2022 BIO International Convention on June 13 - 16, 2022, inRHEA-AIneutral
05/19/22 8:00 AMNasdaq : NMTR 9 Meters Biopharma to Exhibit at Digestive Disease Week 20229 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced that the company will host an exhibit at Digestive Disease Week (DDW) which takes place MayRHEA-AIneutral
05/18/22 8:00 AMNasdaq : NMTR clinical trial9 Meters Biopharma Presents Preclinical Data at the 2022 American Thoracic Society International Conference on the Use of Larazotide in Idiopathic Pulmonary Fibrosis9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced that Matthew Bryant, PharmD, Vice President of Medical Affairs at 9 Meters, delivered a posterRHEA-AIneutral
05/16/22 7:00 AMNasdaq : NMTR earnings9 Meters Biopharma Provides Business Update and Reports Financial Results for First Quarter 2022May 16,RHEA-AIneutral
05/05/22 8:00 AMNasdaq : NMTR conferences9 Meters Biopharma to Present at the H.C. Wainwright Global Investment Conference and the LifeSci Partners Immunology & Inflammation Symposium9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced today that John Temperato, President & Chief Executive Officer of 9 Meters, will present at theRHEA-AIneutral
04/20/22 9:00 AMNasdaq : NMTR clinical trial9 Meters Biopharma and Celiac.com Announce Collaboration to Support Clinical Trial Enrollment in 9 Meter's Phase 3 Study for Celiac Disease9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, and Celiac.com, a news, information, and support website for those on a gluten-freeRHEA-AIneutral
04/13/22 7:00 AMNasdaq : NMTR 9 Meters Biopharma Announces Allowance of Patent for Anti-GIP Monoclonal Antibody NM-136 for the Treatment of Serious Metabolic Conditions9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced today that the Company has received notice from the United States Patent and Trademark OfficeRHEA-AIneutral
03/23/22 7:00 AMNasdaq : NMTR earnings9 Meters Biopharma Provides Business Update and Reports Financial Results for Fourth Quarter and Full Year 20219 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today provided an overview of its recent achievements, important upcoming milestones, and financialRHEA-AIpositive
03/21/22 8:00 AMNasdaq : NMTR conferences9 Meters Biopharma to Present at the Maxim Group 2022 Virtual Growth Conference9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced today that John Temperato, President & Chief Executive Officer of 9 Meters, will present at theRHEA-AIneutral